Hematologic Cancer Research Studies
CML
EA9171: A Phase II Study of adding the anti-PD-1 antibody pembrolizumab to tyrosine kinase inhibitors in patients with chronic myeloid leukemia and persistently detectable minimal residual disease
CLL
EA9161: A Randomized Phase III Study of the addition of Venetoclax to Ibrutinib and Obinutuzumab versus Ibrutinib and Obinutuzumab in Untreated Younger Patients with Chronic Lymphocytic Leukemia (CLL)
B-CELL LYMPHOMA
ADCT-402-201: A Phase 2 Open-Label Single-Arm Study to Evaluate the Efficacy and Safety of Loncastuximab Tesirine in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
B-CELL ALL
A041501: A Phase III Trial to Evaluate the Efficacy of the Addition of Inotuzumab Ozogamicin (a Conjugated Anti-CD22 Monoclonal Antibody) to Frontline Therapy in Young Adults (Ages 18-39 Years) with Newly Diagnosed Precursor B-Cell ALL
MDS
NHLBI-MDS: The National Myelodysplastic Syndromes Natural History Study
AML/MDS
S1612: A Randomized Phase II/III Trial of "Novel Therapeutics" versus Azacitidine in Newly Diagnosed Patients with Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS), Age 60 or Older
FOLLICULAR LYMPHOMA
S1608: Randomized Phase II Trial in Early Relapsing or Refractory Follicular Lymphoma
SMOLDERING MYELOMA
EAA173: Daratumumab to Enhance Therapeutic Effectiveness of Revlimid in Smoldering Myeloma (DETER-SMM)
Cancer Care Delivery Research Studies
A231602CD: Assessing Financial Difficulty in Patients with Blood Cancers